Antimicrobial Resistance Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Department of Family Medicine, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
BMC Infect Dis. 2021 May 18;21(1):450. doi: 10.1186/s12879-021-06168-7.
A protective effect of vitamin D against COVID-19 infection is under investigation. We aimed to analyze the effect of vitamin D sufficiency on the clinical outcomes of patients infected with COVID-19.
In this cross-sectional study we analyzed the vitamin D levels of COVID-19 patients who were admitted to Razi Hospital (an infectious disease referral center in Mazandaran province in northern Iran) from February to March 2020. Overall, a cutoff point of 30 ng/mL was used for the definition of vitamin D sufficiency.
One hundred fifty-three patients were analyzed in this study who had laboratory documentation of a 25(OH) D level at the time of hospitalization. The vitamin D levels of the patients were 27.19 ± 20.17 ng/mL. In total, 62.7% (n = 96) of the patients had a 25(OH) D level of less than 30 ng/mL and 37.25% (n = 57) had a 25(OH) D level of more than 30 ng/mL. In total, 49% (n = 75) of the patients suffered from at least one underlying disease. The univariate and multivariable regression showed that vitamin D sufficiency was not associated with a statistically significant lower risk of adverse clinical outcomes of COVID-19 such as duration of hospitalization and severity of infection (P > 0.05).
Sufficient vitamin D levels were not found to be protective against adverse clinical outcomes in patients infected with COVID-19. Chronic disorders in COVID-19 patients were found to have greater relevance than vitamin D levels in determining the adverse outcomes of the infection. Further studies are needed to determine the role of vitamin D level in predicting the outcomes of COVID-19 infection.
维生素 D 对 COVID-19 感染的保护作用正在研究中。本研究旨在分析维生素 D 充足对 COVID-19 感染患者临床结局的影响。
在这项横断面研究中，我们分析了 2020 年 2 月至 3 月期间入住拉齐医院（伊朗北部马赞达兰省的传染病转诊中心）的 COVID-19 患者的维生素 D 水平。总体而言，使用 30ng/mL 作为维生素 D 充足的定义切点。
本研究共分析了 153 例有住院时 25(OH)D 水平实验室记录的患者。患者的维生素 D 水平为 27.19±20.17ng/mL。共有 62.7%（n=96）的患者 25(OH)D 水平低于 30ng/mL，37.25%（n=57）的患者 25(OH)D 水平高于 30ng/mL。共有 49%（n=75）的患者患有至少一种基础疾病。单变量和多变量回归分析显示，维生素 D 充足与 COVID-19 不良临床结局（如住院时间和感染严重程度）的风险降低无统计学意义相关（P>0.05）。
在 COVID-19 感染患者中，充足的维生素 D 水平与不良临床结局无关。COVID-19 患者的慢性疾病与维生素 D 水平相比，与感染的不良结局更为相关。需要进一步研究来确定维生素 D 水平在预测 COVID-19 感染结局中的作用。
